Biography
Dr. Son Hai Vu is a biomedical scientist with a background in microbiology and immunology, trained in South Korea during his graduate and postdoctoral studies. His research focuses on cancer immunotherapy and regenerative medicine.
Dr. Vu’s work has been supported by academic and industrial funding sources, including ICGEB, Vinmec, and VinUniversity. His projects—particularly engineering iPSC-derived NK cells for cancer treatment and developing patient-derived tumor organoid–based drug testing—aim to bridge physicians and basic scientists to enhance translational and clinical impact. He has also mentored undergraduate students and early-career researchers to help them advance in both academic and industrial settings.
cancer immunotherapy, regenerative medicine, organoid-based tumor modeling
1. Hồ, N.T., Hughes, S.G., Ta, V.T. et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat Commun 15, 4081 (2024).
2. Vu SH, Nguyen HA, Jung S, Lee BS, Nguyen TNQ, Lee H, Lee H-g, Myagmarjav D, Jo T, Choi Y, Lee M-S. SERTAD1 Sensitizes Breast Cancer Cells to Doxorubicin and Promotes Lysosomal Protein Biosynthesis. Biomedicines. 2022; 10(5):1148.
3. Jung S, Myagmarjav D, Jo T, Lee S, Han S, Quynh NTN, Anh NH, Vu SH, Choi Y, Lee MS. Inhibitory role of TRIP-Br1 oncoprotein in anticancer drug-mediated programmed cell death via mitophagy activation. Int J Biol Sci 2022; 18(9):3859-3873.
4. Nguyen TQ, Jung S, Nguyen HA, Lee B, Vu SH, Myagmarjav D, et al. The regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1. J Hematol Oncol. 2022 Jun 16;15(1):82. doi:10.1186/s13045-022-01303-6. PMID:35710446.
He was a Vietnamese delegate in the JENESYS 2.0 program (Cohort 2013). Since joining VinUniversity, Dr. Vu has been selected as a Young Investigator representing Trans-Med VN at the World Immunotherapy Council and the Society for Immunotherapy of Cancer (SITC, Cohort 2024). He also represented Vietnam at the International Workshop on Cell Therapy of Blood Diseases in Tianjin, China (Cohort 2025).